+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID05338190

Study of Subcutaneous Belimumab Plus Rituximab Compared to Rituximab and Placebo in Adults with Persistent or Chronic Primary Immune Thrombocytopenia

Led by Assistance Publique - Hôpitaux de Paris · Updated on 2023-09-11

132

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Primary immune thrombocytopenia ITP is an autoimmune disorder where the bodys immune system attacks its own platelets, leading to low platelet counts and increased bleeding risk. This trial focuses on adults with persistent or chronic ITP who have not had lasting success with standard therapies. Researchers are comparing the effects of combining the drug rituximab with either subcutaneous belimumab or a placebo to see which treatment better improves platelet counts and reduces disease activity over one year. Participants are randomly assigned to one of two groups. One group receives weekly injections of belimumab under the skin for 24 weeks alongside two intravenous doses of rituximab, given one and three weeks after starting treatment. The other group receives placebo injections on the same schedule with the same rituximab dosing. This double-blind study is conducted at multiple international centers and aims to determine if adding belimumab provides better outcomes than rituximab alone. During the study, participants will have regular blood tests to monitor platelet levels, immune cell populations, antibody levels, and signs of infections or low immunoglobulin levels at specific weeks up to two years. Researchers will assess overall response rates at one year and track safety measures, including infections and immune system changes. The total participation time includes treatment and extended follow-up to evaluate both effectiveness and safety over time.

CONDITIONS

Brief Title

Efficacy and Safety of Subcutaneous Belimumab or Placebo in Addition of Rituximab in Persistent or Chronic Immune Thrombocytopenia

Research Team

M

Matthieu MAHEVAS, Professor of medicine

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here